Fitaro and Semaglutide: What This Name Actually Means for UK Patients

You found 'Fitaro semaglutide' online, here is why a UK pharmacy cannot supply it

Picture this: you have been researching weight-loss injections, you spot the name Fitaro in a forum thread or a social media post, you search for it and end up here. That journey makes complete sense, but the name is doing confusing work. Fitaro emerged as a semaglutide brand in certain European markets and has circulated in online discussions, sometimes alongside claims that it is interchangeable with Wegovy or Ozempic. It is not interchangeable in any practical UK sense, because it does not hold a UK marketing authorisation.

The MHRA licenses medicines individually for the UK market. A product approved in another country (even one in the European Economic Area) is not automatically valid here. Wegovy is the semaglutide product that has gone through the MHRA process for weight management, and it is the one a UK prescriber can lawfully prescribe for that purpose. Any website selling something labelled Fitaro to UK patients is either selling an unlicensed import or, worse, something entirely unverified. The MHRA has warned repeatedly about fake and unlicensed weight-loss products sold online, and large seizures of counterfeit pens have taken place across the UK. If you are ever unsure whether an online pharmacy is legitimate, you can check its registration on the GPhC register. Every legal UK online pharmacy must appear there.

The upshot: if semaglutide for weight management is what you are looking for, Wegovy is the route. Fitaro is not that route in the UK.

What semaglutide actually does, and why the trial data matters

A question our prescribers hear most weeks is some version of: does this medicine actually work, or is it hype? The evidence for semaglutide 2.4mg (Wegovy) is substantial. The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks. Participants using semaglutide 2.4mg alongside lifestyle changes lost an average of around 15% of their body weight, compared with roughly 2.4% on placebo. Those are trial averages, not guarantees for any individual, and results vary, but the scale of the difference is what made NICE take notice.

The mechanism is straightforward once you know how the gut communicates with the brain. Semaglutide is a GLP-1 receptor agonist: it mimics glucagon-like peptide-1, a hormone your gut releases after eating. By activating GLP-1 receptors, it slows gastric emptying, reduces appetite and makes food feel satisfying sooner. The result is that many people find they eat less without fighting constant hunger. Alongside reduced-calorie eating and increased activity, that shift adds up. You can read more about how semaglutide works and the broader evidence base in our detailed guide.

In June 2026 the MHRA also approved an oral semaglutide tablet (Wegovy tablets) for weight management, the first of its kind licensed in the UK. That expands the options for people who prefer not to inject, though the clinical profile differs from the injection. The full Wegovy overview covers both formats.

Who the UK licence covers, and what makes this a prescriber's decision

The Wegovy injection is licensed for UK adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds under UK guidance, the adjustment is 2.5 kg/m² for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. NICE's appraisal of semaglutide (TA875) also sets out NHS-specific conditions, including a maximum treatment duration of two years within specialist weight management services.

None of that means you simply enter a BMI and get a prescription. A prescriber considers your full medical picture: medications you already take, your history, whether weight-related conditions are present, whether there are reasons semaglutide would not be suitable. Certain conditions (a personal or close family history of medullary thyroid carcinoma, a history of pancreatitis, or some gastrointestinal disorders) require careful discussion. Semaglutide is not recommended during pregnancy or breastfeeding, and it is not licensed for under-18s. If you are planning to conceive, that is a conversation to have with your prescriber before starting.

The point is that the licence sets out a population; whether you fit is clinical, not algorithmic. Our weight-loss treatment overview explains what that assessment involves. If you want to understand what private treatment costs in context, the Wegovy cost guide covers what is typically included in a transparent price and what to look out for.

Side effects, safety monitoring and what to do if something feels wrong

Semaglutide's side-effect profile is dominated by gastrointestinal symptoms: nausea, loose stools or constipation, indigestion and sometimes vomiting are the most commonly reported. These tend to be most noticeable in the first few days after starting or after a dose increase, and for many people they ease over a couple of weeks as the body adjusts. If you are working through the early stages of treatment, our guide to semaglutide 1 covers what to expect at the starting dose, while our guide to semaglutide 2 explains what changes as the dose steps up. The NHS patient information for semaglutide lists these clearly alongside the rarer effects worth knowing.

A small number of people experience more serious reactions. Severe, persistent stomach pain that radiates to the back (with or without vomiting) needs urgent medical attention, because it can signal pancreatitis. Gallbladder problems, signs of dehydration from prolonged vomiting or diarrhoea, and allergic reactions are also in the category of things that need same-day medical review rather than waiting. If you are already on the medicine and anything feels unexpectedly severe or persistent, call 111 or contact your GP. Side effects can also be reported directly through the MHRA's Yellow Card scheme, that reporting helps regulators spot patterns across the population using the medicine.

Mounjaro (tirzepatide) has a broadly similar GI side-effect profile but activates two receptors rather than one. If you are weighing the options, our guide on Wegovy and body composition touches on some of the practical differences patients ask about.